[Special Stock] HK Inno.N Rises on Expectations of K-CAB's Overseas Growth

HK Innoen's stock price is on the rise. Expectations for overseas growth of K-CAB in the second half of the year appear to be influencing the stock price.

As of 9:34 AM on the 12th, HK Innoen is trading at 41,600 KRW, up 1.96% from the previous day.

Lee Jisoo, a researcher at Daol Investment & Securities, said, "Sales growth is expected due to the expansion of K-CAB's launch countries and increased sales in China." He added, "Phase 3 clinical data for non-erosive patients in the U.S. is expected in the second half of the year, and clinical data for erosive patients is expected to be announced in the first half of 2025," noting, "Approval applications for two indications are anticipated after the data release." He also stated, "A sharp increase in prescriptions is expected upon K-CAB's launch in the U.S.," and added, "We expect a revaluation of corporate value once overseas performance is confirmed."